POLA1 and diffuse large B-cell lymphoma: The antibody–drug conjugate (ADC) polatuzumab vedotin (pola; Polivy®) was approved by the United States Food and Drug Administration in June 2019 for use in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in combination with bendamustine and rituximab (BR), for patients who have received two or more prior therapies [1].